FBLG
FibroBiologics Inc (FBLG)
Healthcare • NASDAQ • $0.77+2.55%
- Symbol
- FBLG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.77
- Daily Change
- +2.55%
- Market Cap
- $4.01M
- Trailing P/E
- N/A
- Forward P/E
- -0.17
- 52W High
- $15.50
- 52W Low
- $0.77
- Analyst Target
- $13.50
- Dividend Yield
- N/A
- Beta
- 1.15
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Company websiteResearch FBLG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.